An Exploratory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies (Phase 2 study)

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221994

Enrollment

150

Registered

2012-12-28

Start date

2012-12-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsonism in Dementia with Lewy Bodies

Interventions

investigational material(s) Generic name etc : AD-810N(Zonisamide) INN of investigational material : Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients met the diagnostic criteria of probable DLB -Outpatients -Patients taking L-DOPADCI in succession more than 12 weeks etc.

Exclusion criteria

Exclusion criteria: -Patients with parkinsonism excepting Dementia with Lewy Bodies -Patients with Parkinson's disease with dementia -Epileptic patients -Patients treated with zonisamide etc.

Design outcomes

Primary

Measure	Time frame
Efficacy : UPDRS Part III	—

Secondary

Measure	Time frame
Efficacy : MMSE etc	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026